World's Best Scientists 2026 revealed!
Paul Declerck

Paul Declerck

D-Index & Metrics

Biology and Biochemistry

D-Index
69
Citations
15750
World Ranking
7454
National Ranking
137

Overview

Paul Declerck is affiliated with KU Leuven in Belgium. Their research spans multiple fields, with a primary focus on medicine and biochemistry, genetics, and molecular biology. Declerck's work particularly emphasizes several subfields including genetics, immunology, molecular biology, hematology, and radiology, nuclear medicine, and imaging.

The scientist's publications feature significant contributions to topics such as inflammatory bowel disease, blood coagulation and thrombosis mechanisms, monoclonal and polyclonal antibodies research, biosimilars and bioanalytical methods, immunodeficiency and autoimmune disorders, microscopic colitis, and protease and inhibitor mechanisms.

Recent papers authored or co-authored by Declerck include:

  • A Narrative Review on Plasminogen Activator Inhibitor-1 and Its (Patho)Physiological Role: To Target or Not to Target?, 2021, International Journal of Molecular Sciences
  • The Efficacy, Safety, and Immunogenicity of Switching Between Reference Biopharmaceuticals and Biosimilars: A Systematic Review, 2020, Clinical Pharmacology & Therapeutics
  • Targeting PAI-1 in Cardiovascular Disease: Structural Insights Into PAI-1 Functionality and Inhibition, 2020, Frontiers in Cardiovascular Medicine
  • Thrombin Activatable Fibrinolysis Inhibitor (TAFI): An Updated Narrative Review, 2021, International Journal of Molecular Sciences
  • Nonmedical Switching From Originators to Biosimilars: Does the Nocebo Effect Explain Treatment Failures and Adverse Events in Rheumatology and Gastroenterology?, 2020, Rheumatology and Therapy

Their collaborative work involves frequent co-authors, including:

  • Nick Geukens
  • Séverine Vermeire
  • Bram Verstockt
  • Erwin Dreesen
  • Kevin Hollevoet

Paul Declerck has published multiple articles in specialized journals, illustrating their expertise and continuing research engagement. Notable publication venues include:

  • Journal of Crohn's and Colitis
  • International Journal of Molecular Sciences
  • bioRxiv (Cold Spring Harbor Laboratory)
  • Cancer Gene Therapy
  • Pharmaceutics

Their scientific inquiry mainly addresses critical medical challenges through a molecular and genetic lens. The research contributions encompass inflammatory bowel disease and mechanisms related to blood coagulation and thrombosis, with an emphasis on antibody research and bioanalytical approaches to biosimilars. Furthermore, ongoing investigation in protease and inhibitor mechanisms alongside autoimmune and immunodeficiency disorders forms an integral part of their work.

Best Publications

  • Measurement of plasminogen activator inhibitor 1 in biologic fluids with a murine monoclonal antibody-based enzyme-linked immunosorbent assay.

    Paul Declerck;M C Alessi;M Verstreken;E K O Kruithof

  • Purification and characterization of a plasminogen activator inhibitor 1 binding protein from human plasma. Identification as a multimeric form of S protein (vitronectin).

    P J Declerck;M De Mol;M C Alessi;S Baudner

  • Insulin stimulates the synthesis of plasminogen activator inhibitor 1 by the human hepatocellular cell line Hep G2.

    M C Alessi;I Juhan-Vague;T Kooistra;Paul Declerck

  • The pro- or antiangiogenic effect of plasminogen activator inhibitor 1 is dose dependent

    Laetitia Devy;Silvia Blacher;Christine Grignet-Debrus;Khalid Bajou

  • Effectiveness of the Electronic Cigarette: An Eight-Week Flemish Study with Six-Month Follow-up on Smoking Reduction, Craving and Experienced Benefits and Complaints

    Karolien Adriaens;Dinska Van Gucht;Paul Declerck;Frank Baeyens

  • Plasma plasminogen activator inhibitor-1 in angina pectoris. Influence of plasma insulin and acute-phase response.

    I Juhanvague;Mc Alessi;P Joly;X Thirion

  • Plasminogen activator inhibitor-1 promotes angiogenesis by stimulating endothelial cell migration toward fibronectin

    Chiho Isogai;Walter E. Laug;Hiroyuki Shimada;Paul J. Declerck

  • Age-Dependent Spontaneous Coronary Arterial Thrombosis in Transgenic Mice That Express a Stable Form of Human Plasminogen Activator Inhibitor-1

    Mesut Eren;Corrie A. Painter;James B. Atkinson;Paul J. Declerck

  • Comparison of random and oriented immobilisation of antibody fragments on mixed self-assembled monolayers.

    Kristien Bonroy;Filip Frederix;Gunter Reekmans;Ellen Dewolf

  • Multimeric vitronectin. Identification and characterization of conformation-dependent self-association of the adhesive protein

    A Stockmann;S Hess;Paul Declerck;R Timpl

  • Identification of a conformationally distinct form of plasminogen activator inhibitor-1, acting as a noninhibitory substrate for tissue-type plasminogen activator.

    Paul Declerck;M De Mol;D E Vaughan;Desire Collen

  • Host-derived plasminogen activator inhibitor-1 (PAI-1) concentration is critical for in vivo tumoral angiogenesis and growth.

    Khalid Bajou;Catherine Maillard;Maud Jost;Roger H Lijnen

  • Plasminogen activator inhibitor 1 may promote tumour growth through inhibition of apoptosis

    HC Kwaan;J Wang;K Svoboda;Paul Declerck

  • Three decades of research on plasminogen activator inhibitor-1: a multifaceted serpin.

    Paul J. Declerck;Ann Gils

  • Plasminogen activator inhibitor-1

    Ann Gils;Paul J Declerck

  • Plasminogen activator inhibitor-1 modulates adipocyte differentiation

    Xiubin Liang;Talerngsak Kanjanabuch;Su-Li Mao;Chuan-Ming Hao

  • Structural requirements for the extracellular interaction of plasminogen activator inhibitor 1 with endothelial cell matrix-associated vitronectin.

    K T Preissner;J Grulich-Henn;H J Ehrlich;Paul Declerck

  • Mechanisms contributing to the conformational and functional flexibility of plasminogen activator inhibitor-1.

    Kathleen Aertgeerts;Hendrik L. De Bondt;Camiel J. De Ranter;Paul J. Declerck

  • Hormonal control of plasminogen activator inhibitor-1 gene expression and production in human adipose tissue: stimulation by glucocorticoids and inhibition by catecholamines.

    Christine M Halleux;Paul J Declerck;Sinh L Tran;Roger Detry

  • The Language of Biosimilars: Clarification, Definitions, and Regulatory Aspects

    Paul Declerck;Romano Danesi;Danielle Petersel;Ira Jacobs

Frequent Co-Authors

Desire Collen
Desire Collen KU Leuven
Irène Juhan-Vague
Irène Juhan-Vague Hôpital de la Timone
Marie-Christine Alessi
Marie-Christine Alessi Aix-Marseille University
Douglas E. Vaughan
Douglas E. Vaughan Northwestern University
Peter A. Andreasen
Peter A. Andreasen Aarhus University
Serge Muyldermans
Serge Muyldermans Vrije Universiteit Brussel

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Best Scientists Citing Paul Declerck

Trending Scientists